Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cocarboxylase. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | TKT | P29401 | 7/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PPP5C | P53041 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cocarboxylase SCHEMBL23151792 | 1.00 | LMNA (0.98) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL4315554 | 0.99 | LMNA (0.96) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL662896 | 0.99 | LMNA (0.96) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL23151791 | 0.99 | LMNA (0.96) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL80028 | 0.99 | LMNA (1.00) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL30192281 | 0.99 | LMNA (1.00) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL23151779 | 0.98 | LMNA (0.94) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL23151785 | 0.98 | LMNA (0.98) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL8923435 | 0.98 | LMNA (0.98) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL28756433 | 0.98 | LMNA (0.98) | LMNATKTTDP1HSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108191912-A | The preparation method of 12 kinds of vitamin raw materials Cocarboxylase Tetrahydrates of injection | 山西普德药业有限公司 | 2018-06-22 | — | — | CN | claimed |
| WO-2025052869-A1 | EXTERNAL-USE COMPOSITION AND METHOD FOR ENHANCING FRAGRANCE OF SAME | ロート製薬株式会社 | 2025-03-13 | — | — | WO | disclosed |
| CN-117545459-A | Cleaning composition and method for producing same | 日本乐敦制药株式会社 | 2024-02-09 | — | — | CN | disclosed |
| CN-116870157-A | Composition for improving skin disorders | 日本乐敦制药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| EP-3995151-B1 | LIPID COMPOSITION FOR ENCAPSULATING AN ACTIVE SUBSTANCE AND ALLOWING CONTROL OF THE SPEED OF RELEASE OF SAID ACTIVE SUBSTANCE | SOC DEXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2023-09-13 | — | — | EP | disclosed |
| CN-116685305-A | Cleaning composition | 日本乐敦制药株式会社 | 2023-09-01 | — | — | CN | disclosed |
| CN-111107831-B | Composition for supplementing the taste of young women | 日本乐敦制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| US-11246853-B2 | Method for evaluating the ability of a composition to prevent muscle damage and fatigue; food supplement and drug | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2022-02-15 | — | — | US | disclosed |
| US-11248156-B2 | Borehole fluid with a thiamine-based shale inhibitor | HALLIBURTON ENERGY SERVICES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210338633-A1 | METHOD FOR EVALUATING THE ABILITY OF A COMPOSITION TO PREVENT MUSCLE DAMAGE AND FATIGUE; FOOD SUPPLEMENT AND DRUG | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2021-11-04 | — | — | US | disclosed |
| CN-106456484-A | External preparation | 乐敦制药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-20130210921-A1 | Method for Giving Warmth to Skin | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| CN-102232952-A | Photoaging inhibitor and skin thinning inhibitor | ROHTO PHARMA | 2011-11-09 | — | — | CN | disclosed |
| US-20110027326-A1 | External Composition for Skin | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2269652-A1 | COMPOSITION FOR EXTERNAL APPLICATION TO SKIN | Rohto Pharmaceutical Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100209364-A1 | Emulsified Composition | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100021405-A1 | EXTERNAL PREPARATION FOR SKIN | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
| US-20080207560-A1 | Composition For External Use | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1849481-A1 | COMPOSITION FOR EXTERNAL USE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246853-B2 | Method for evaluating the ability of a composition to prevent muscle damage and fatigue; food supplement and drug | GYS1, PYGM, MYOF | HSP90AA1 2398/4885LMNA 1680/4885TKT 3096/4885 |
| US-20210338633-A1 | METHOD FOR EVALUATING THE ABILITY OF A COMPOSITION TO PREVENT MUSCLE DAMAGE AND FATIGUE; FOOD SUPPLEMENT AND DRUG | PYGM, TNNC1, GYS1 | HSP90AA1 600/4885LMNA 369/4885TKT 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.